Production (Stage)
Arbutus Biopharma Corporation
ABUS
$3.22
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.76M | 1.57M | 1.34M | 1.73M | 1.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.76M | 1.57M | 1.34M | 1.73M | 1.53M |
| Cost of Revenue | 8.96M | 8.81M | 14.27M | 15.55M | 15.40M |
| Gross Profit | -7.20M | -7.24M | -12.93M | -13.83M | -13.87M |
| SG&A Expenses | 5.83M | 8.43M | 4.54M | 7.55M | 5.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.79M | 17.24M | 18.81M | 23.10M | 20.72M |
| Operating Income | -13.03M | -15.67M | -17.47M | -21.37M | -19.18M |
| Income Before Tax | -24.53M | -12.53M | -19.72M | -19.80M | -17.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.53M | -12.53M | -19.72M | -19.80M | -17.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.53M | -12.53M | -19.72M | -19.80M | -17.88M |
| EBIT | -13.03M | -15.67M | -17.47M | -21.37M | -19.18M |
| EBITDA | -12.70M | -15.34M | -17.14M | -21.02M | -18.83M |
| EPS Basic | -0.13 | -0.07 | -0.10 | -0.11 | -0.10 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.05 | -0.07 | -0.06 |
| EPS Diluted | -0.13 | -0.07 | -0.10 | -0.11 | -0.10 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.05 | -0.07 | -0.06 |
| Average Basic Shares Outstanding | 190.71M | 189.70M | 189.00M | 188.04M | 175.63M |
| Average Diluted Shares Outstanding | 190.71M | 189.70M | 189.00M | 188.04M | 175.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |